Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 p.m. PT / 3:00 p.m. ET in San Francisco.
The company said the live presentation and replay will be available on its investor Events page at https://investors.lexpharma.com/.
Positive
- None.
Negative
- None.
News Market Reaction – LXRX
In the Jan 7 session, LXRX gained 2.63%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.5% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Preclinical data | Positive | +0.8% | Publication of ACSL5 preclinical data supporting LX9851’s scientific rationale. |
| Dec 05 | Clinical presentation | Positive | -1.4% | Upcoming sotagliflozin adipose distribution data presentation at CVCT 2025. |
| Nov 25 | Investor conferences | Neutral | -0.7% | December investor conference appearances with webcast access for investors. |
| Nov 11 | Investor conference | Neutral | +9.9% | Jefferies London Healthcare Conference fireside chat announcement. |
| Nov 06 | Earnings/R&D update | Positive | +3.6% | Q3 2025 financial results and broad pipeline progress, including LX9851 and SONATA-HCM. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows generally positive alignment between upbeat news (preclinical data, conferences, earnings) and modest price gains, but data-focused clinical presentations have occasionally seen negative reactions.
Over the past few months, Lexicon reported Q3 2025 results with revenue of $14.2M and an improved net loss of $12.8M, supported by a Novo Nordisk upfront payment and INPEFA sales. It highlighted pipeline progress, including LX9851 and pilavapadin, and announced multiple conference participations and a preclinical LX9851 publication on Dec 10, 2025. Today’s J.P. Morgan conference appearance fits this pattern of ongoing investor and scientific outreach rather than a new financial or clinical inflection point.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco.
The live event and replay of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
